Hormonal
GLP-1-based therapies (liraglutide, semaglutide, tirzepatide) reduce blood pressure in individuals with overweight or obesity, with tirzepatide demonstrating the greatest magnitude of reduction.
If you have high blood pressure and carry extra weight, GLP-1 medications like semaglutide or tirzepatide can lower your blood pressure, sometimes allowing you to take fewer other blood pressure pills. Tirzepatide appears to lower blood pressure more than other options in this class. These are weekly injections, which might be easier to manage than daily pills, though they can cause stomach side effects.
Among them, tirzepatide led to the largest decreases in SBP (−6.45 mmHg) and DBP (−3.64 mmHg).
Why this rating
Based on multiple RCTs and meta-analyses cited, though no direct RHTN-specific trials exist yet.
Source
GLP-1-based therapies for the treatment of resistant hypertension in individuals with overweight or obesity: a review
Candace Jarade et al. · EClinicalMedicine · 2024
DOI 10.1016/j.eclinm.2024.102789
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →